spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  amphetamine 

 HSMN NewsFeed - 21 Jul 2021
Corium Launches Innovative ADHD Treatment AZSTARYS(TM) (serdexmethylphenidate and dexmethylphenidate) in the U.S. for Patients Age 6 Years and Older
Biopharmaceutical Neurology Product Launch
 HSMN NewsFeed - 13 May 2020
Arbor Pharmaceuticals Announces FDA Filing Acceptance of New Drug Application (NDA) for AR19, an Investigational ADHD Prescription Stimulant Treatment Specifically Designed to Resist Physical Manipulation for Nonmedical Misuse or Abuse
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Dec 2019
Lannett To Commence Marketing Generic Adderall(R) XR
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 11 Mar 2019
Lannett Enters Into Distribution Agreement For Generic Adderall(R)
Biopharmaceuticals Generics Distribution
 HSMN NewsFeed - 7 Sep 2018
BDD Pharma and Cingulate Therapeutics Announce License Agreement With OralogiK(TM) Enabled Triple Pulse Products
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 31 May 2018
Cingulate Therapeutics Strengthens Leadership with Two New Board Appointments
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 10 Jul 2017
Cingulate Therapeutics Appoints Strategic Finance Veteran Louis G. Van Horn as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Mar 2017
Acura Pharmaceuticals and MainPointe Pharmaceuticals Announce Deal for Nexafed(R) Products
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 8 Nov 2016
Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant for Contrave(R) (naltrexone HCl / bupropion HCl extended release) in Australia and New Zealand
Biopharmaceuticals Distribution
 HSMN NewsFeed - 1 Aug 2016
Orexigen Completes Acquisition of All U.S. Rights to Contrave(R) and Launches U.S. Sales Organization
Biopharmaceuticals Acquisitions Product Launch
 HSMN NewsFeed - 1 Aug 2016
Mylan Launches Generic Dexedrine(R) Capsules
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 8 Jun 2016
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave(R) Patent Litigation
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 16 May 2016
Neos Therapeutics Announces U.S. Launch of Adzenys XR-ODT(TM) (Amphetamine Extended-Release Orally Disintegrating Tablet) for the Treatment of ADHD in Patients Six Years and Older
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 17 Feb 2016
Impax Receives FDA Approval for Generic Version of Adderall XR(R) (mixed salts of a single-entity amphetamine product) Capsules, CII
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 28 Jan 2016
Neos Therapeutics Announces FDA Approval of Adzenys XR-ODT(TM) (Amphetamine Extended-Release Orally Disintegrating Tablet) for the Treatment of ADHD in Patients 6 Years and Older
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 21 May 2015
Tris Pharma Announces the FDA Acceptance of NDA for Dyanavel(TM) XR
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 8 May 2014
Acura Pharmaceuticals Announces Settlement of Patent Litigation With Ranbaxy Inc.
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 10 Jul 2013
Tris Pharma's Generic Pharmaceuticals Business Launches Dextroamphetamine Sulfate Oral Solution
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 3 Apr 2013
Collegium Pharmaceutical Names Douglas Carlson to Vice President of Business Development
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 17 Jan 2013
Collegium Pharmaceutical Announces Relocation to Massachusetts
Biopharmaceuticals
 HSMN NewsFeed - 26 Apr 2010
Mylan Begins Marketing First Generic Version of Desoxyn(R)
Biopharmaceuticals Generics
 HSMN NewsFeed - 12 Apr 2010
Sinapis Pharma Receives IND Approval from the FDA
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 19 Jan 2010
OraSure Technologies and Roche Diagnostics Sign Worldwide Commercialization Agreement for Fully Automated Oral Fluid Drugs of Abuse Assays
Diagnostics
 HSMN NewsFeed - 1 Jul 2009
Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment
Biopharmaceuticals
 HSMN NewsFeed - 23 Apr 2009
Sciele Pharma and Addrenex Pharmaceuticals Announce Positive Phase III Clinical Results of Clonicel Used in Combination with Stimulants to Treat ADHD
Biopharmaceuticals
 HSMN NewsFeed - 2 Apr 2009
Teva Introduces First Generic Adderall XR Capsules in the United States
Biopharmaceuticals Generics
 HSMN NewsFeed - 31 Mar 2009
Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
Biopharmaceuticals
 HSMN NewsFeed - 16 Mar 2009
Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 7 Oct 2008
Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
Biopharmaceuticals
 HSMN NewsFeed - 23 Apr 2008
FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Mar 2008
Auriga Laboratories Announces FDA Approval of Liquadd(TM) (Dextroamphetamine Sulfate) Oral Solution for the Treatment of ADHD and Upcoming Product Launch
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Feb 2008
FDA Accepts for Review OVATION's Two NDA Submissions for Sabril(R)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 3 Jan 2008
FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Jan 2008
Noven Announces Changes to Board of Directors and Senior Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Nov 2007
Yaupon Therapeutics Closes $14.5 Million Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 25 Oct 2007
Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting
Biopharmaceuticals
 HSMN NewsFeed - 4 Sep 2007
Noven Provides Update on Daytrana(TM) Methylphenidate Transdermal System
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 27 Jul 2007
Shire's New ADHD Medication, VYVANSE(TM) (lisdexamfetamine dimesylate) Now Available in U.S. Pharmacies Nationwide
Biopharmaceuticals
 HSMN NewsFeed - 29 Jun 2007
Shire Announces Filing of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults
Biopharmaceuticals
 HSMN NewsFeed - 20 Jun 2007
Noven & Shire to Develop New Transdermal Patch For ADHD
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 18 Jun 2007
Cephalon Receives FDA Approval of NUVIGIL(TM) for the Treatment of Excessive Sleepiness Associated with Three Disorders
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Jun 2007
Shire's ELAPRASE(TM) (idursulfase) Approved by Health Canada for Treatment of Hunter Syndrome
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Jun 2007
International Movement Disorder Specialists Receive New Information About the Use of Once-Daily AZILECT(R) in the Treatment of Parkinson's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 22 May 2007
Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of LIALDA(TM) (mesalamine) Presented at DDW
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 19 May 2007
FDA Issues Approvable Letter for SPD465 (Triple-Bead Mixed Amphetamine Salts) for the Treatment of ADHD in Adults
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 May 2007
Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many Aspects of Daily Life
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 3 May 2007
VYVANSE(TM) (lisdexamfetamine dimesylate) Receives Final DEA Schedule Classification, Clearing Way for Launch of First Prodrug Stimulant for Treatment of ADHD
Biopharmaceuticals
 HSMN NewsFeed - 20 Apr 2007
Shire Completes Acquisition of New River
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 18 Apr 2007
Shire Successfully Completes Tender Offer for New River Shares
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 4 Apr 2007
Catalyst Pharmaceutical Partners, Inc. Names Vice President of Pharmaceutical Development and Project Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Mar 2007
ADDERALL XR(R) - Shire Files Suit Against Colony Pharmaceuticals, Inc., Actavis, Inc. and Actavis Group hf
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 20 Mar 2007
Shire Begins External Search for President of Successful Human Genetic Therapies Business, on Retirement of David Pendergast at the End of 2007
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Mar 2007
LIALDA(TM) (mesalamine) With MMX(TM) Technology - the First Oral Once-Daily Mesalamine for Active, Mild to Moderate Ulcerative Colitis - Now Available
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 5 Mar 2007
UK Launch Expands Global Reach of FOSRENOL(R)
Biopharmaceuticals
 HSMN NewsFeed - 20 Feb 2007
Shire Agrees to Acquire New River to Gain Full Control of VYVANSE(TM), its Future Flagship Product for ADHD
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 16 Jan 2007
FDA Approves LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine for Patients With Active, Mild to Moderate Ulcerative Colitis
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 12 Jan 2007
Catalyst Pharmaceutical Partners, Inc. Adds Thomas Kosten, M.D. to Its Scientific Advisory Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Jan 2007
ELAPRASE(R) for the Treatment of Hunter Syndrome Approved by the European Commission
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Jan 2007
The European Commission Approves First and Only Enzyme Replacement Therapy for Hunter Syndrome
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 Dec 2006
Largest Disease Modification Trial for Parkinson's Disease Completes Enrollment
Biopharmaceuticals Neurology
 HSMN NewsFeed - 22 Dec 2006
New River Pharmaceuticals and Shire Receive Approvable Letter for VYVANSE(TM) (lisdexamfetamine dimesylate) for the Treatment of ADHD
Biopharmaceuticals
 HSMN NewsFeed - 12 Dec 2006
Dr. Jeffrey Leiden Appointed Non Executive Director at Shire
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Nov 2006
FOSRENOL(R) Data Show Evidence of Trends Towards Improved Bone Formation in CKD Stage 5 Patients, New Data Presented at ASN Meeting
Biopharmaceuticals
 HSMN NewsFeed - 16 Nov 2006
Shire Announces Study Results With Once-Daily Guanfacine Extended Release (GXR) in ADHD Patients Aged 6-17
Biopharmaceuticals
 HSMN NewsFeed - 16 Nov 2006
Shire Announces Results of its Bioequivalence Study of SPD465, an Investigational Drug for Adults with ADHD
Biopharmaceuticals
 HSMN NewsFeed - 16 Nov 2006
Shire Announces Results of a Meta-Analysis Comparing Stimulant Medications to Non-Stimulant Medications in Treating ADHD in Patients Aged 8 to 15
Biopharmaceuticals
 HSMN NewsFeed - 13 Nov 2006
Yaupon Therapeutics Closes $4 Million Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 10 Nov 2006
Shire Sues Andrx Pharmaceuticals, L.L.C.
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 26 Oct 2006
DAYTRANA(TM) (methylphenidate transdermal system) Provides Individualized Symptom Management
Biopharmaceuticals
 HSMN NewsFeed - 6 Oct 2006
New River Pharmaceuticals Inc. Receives Approvable Letter for NRP104
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Oct 2006
Roche Diagnostics and OraSure Technologies Sign Letter of Intent to Develop Fully Automated Oral Fluid Drugs of Abuse Assays
Diagnostics
 HSMN NewsFeed - 28 Sep 2006
Barr Cleared to Launch ADDERALL(R) IR
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 7 Sep 2006
Catalyst Pharmaceutical Partners, Inc. Appoints Chief Medical Officer and Vice President of Regulatory Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Jul 2006
Biosite(R) Announces FDA Clearance to Market Triage(R) TOX Drug Screen
Diagnostics FDA
Return to NewsFeed  

 Additional items found! 49

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 49 additional stories matching:
amphetamine
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.